Galecto, Inc. (NASDAQ:GLTO – Get Free Report) was the recipient of a large decline in short interest in October. As of October 15th, there was short interest totalling 9,400 shares, a decline of 36.1% from the September 30th total of 14,700 shares. Approximately 0.9% of the company’s stock are sold short. Based on an average daily trading volume, of 35,400 shares, the short-interest ratio is currently 0.3 days.
Wall Street Analyst Weigh In
Separately, Oppenheimer upped their price target on shares of Galecto from $9.00 to $10.00 and gave the stock an “outperform” rating in a research note on Thursday, October 17th.
Check Out Our Latest Stock Analysis on Galecto
Galecto Price Performance
Galecto (NASDAQ:GLTO – Get Free Report) last announced its quarterly earnings results on Monday, August 12th. The company reported ($4.00) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($8.00) by $4.00. On average, equities research analysts anticipate that Galecto will post -18.08 earnings per share for the current fiscal year.
About Galecto
Galecto, Inc, a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB2064, a selective oral small molecule inhibitor of LOXL2 that is in Phase 2a clinical trial for the treatment of fibrotic diseases, including cancer and myelofibrosis; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis.
Read More
- Five stocks we like better than Galecto
- How to Invest in the Best Canadian StocksĀ
- Is McDonald’s Stock a Smart Buy After Sell-Off and Earnings?
- How to Invest in the FAANG Stocks
- QuantumScape: Solid State EV Batteries Nearing Commercialization
- What is a Bond Market Holiday? How to Invest and Trade
- MicroStrategy: Is This Bitcoin-Powered Stock a Buy or a Gamble?
Receive News & Ratings for Galecto Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galecto and related companies with MarketBeat.com's FREE daily email newsletter.